Search
Home
News
Coins2Day 500
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Great Place To Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
Coins2Day 500
Coins2Day 500
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Great Place To Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
Jen Wieczner
Stay informed with Jen Wieczner’s coverage and analysis for Coins2Day.
Page 47 of 51
Finance
This is how much money the arrested trader made on the ‘flash crash’
By
Financial Writer
Finance
Mylan plays monkey-in-the-middle of hostile takeover battles
By
News Correspondent
Retail
Bra retailer Frederick’s of Hollywood goes bust
By
Market Analyst
Tech
Government lawyers don’t want Comcast and Time Warner Cable to merge
By
Digital Assets Editor
Finance
Why GE could retake throne as king of all dividend stocks
By
Investment Desk
Finance
Biotech “bubble” popped, time to buy again?
By
Market Analyst
Tesla investors do the electric slide
By
Industry Analyst
Features
How Biogen scored the most successful Alzheimer’s drug so far
By
Research Team
Tech
Biotech pros’ top 8 stock picks
By
Financial Writer
MPW
Clinton Foundation appoints Donna Shalala as new leader
By
Market Analyst
Leadership
WeWork’s utopian vision of your future life—in the office
By
News Correspondent
Finance
This is the only commodity to fall more than oil
By
Crypto Correspondent
Finance
Fat Pharma: Pfizer-Hospira and the top 10 overpriced drug deals ever
By
Contributing Writer
Features
In speed mode, FDA approves Pfizer’s big new drug early
By
Investment Desk
Finance
After Allergan loss, is Valeant dumpster diving?
By
Blockchain Reporter